James Splichal, MD
Hematology & Oncology · Athens, GANPI 1588619142
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,143 of the $21,887 with a category attached, or 87.5%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 1,005 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Merck$2K
- Johnson & Johnson$1K
- Bristol Myers Squibb$922
- Pfizer$795
- Seagen Inc.$761
- plus $12K from 54 others
Across 24 payments — averaging $15,187 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$164K
- Merck$79K
- Janssen Research & Development, LLC$46K
- Acerta Pharma LLC$29K
- Regeneron$24K
- AstraZeneca$21K
- plus $19 from 1 others
What the payments were for
- Food & beverage$19,14387%
- Education$5623%
- Other$2,18110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,887 in reported general payments places this provider in the 80th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 55 | $761,212 |
| CabometyxCabozantinib S-Malate | 30 | $751,397 |
| RevlimidLenalidomide | 23 | $386,534 |
| ProcritEpoetin Alfa | 265 | $353,767 |
| TagrissoOsimertinib Mesylate | 19 | $305,876 |
| XgevaDenosumab | 76 | $232,251 |
| IbrancePalbociclib | 15 | $220,020 |
| JakafiRuxolitinib Phosphate | 19 | $218,675 |
| PromactaEltrombopag Olamine | 12 | $208,767 |
| LynparzaOlaparib | 13 | $202,231 |
| ImbruvicaIbrutinib | 12 | $184,420 |
| Somatuline DepotLanreotide Acetate | 18 | $154,878 |
| Lupron DepotLeuprolide Acetate | 26 | $150,126 |
| NinlaroIxazomib Citrate | 12 | $146,347 |
| VenclextaVenetoclax | 13 | $125,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $312 | $761,21255 claims |
| Exelixis Inc.Cabometyx | $218 | $751,39730 claims |
| AstraZenecaTagrisso, Lynparza | $616 | $508,10732 claims |
| Johnson & JohnsonProcrit, Xarelto | $1,062 | $431,974349 claims |
| Bristol Myers SquibbRevlimid | $922 | $386,53423 claims |
| PfizerIbrance, Eliquis | $795 | $324,475149 claims |
| AmgenXgeva, Prolia | $498 | $309,150121 claims |
| AbbVieLupron Depot, Venclexta | $453 | $275,28839 claims |
| Incyte CorporationJakafi | $611 | $218,67519 claims |
| NovartisPromacta | $3,840 | $208,76712 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $330 | $184,42012 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $172 | $154,87818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Athens
- Priya RudolphAthens$745K
- Amanda HathawayAthens$159K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.